MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z
  • L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

    N. Malek, S. Kanavou, M. Lawton, K. Grosset, V. Pitz, N. Bajaj, R. Barker, D. Burn, T. Foltynie, J. Hardy, N. Wood, N. Williams, H. Morris, Y. Ben-Shlomo, D. Grosset (Ipswich, United Kingdom)

  • L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson’s Disease

    D. Su, W. Hu, X. Zhao, Z. Liu, H. Ma, J. Zhou, T. Feng (Beijing, China)

  • Lack of TMEM230 mutations in patients with familial and sporadic Parkinson’s disease in a Taiwanese population

    T. Fan, C. Lin, H. Lin, M. Chen, R. Wu (Taoyuan, Taiwan)

  • Late onset Huntington’s disease in an Argentinian cohort

    M. Cesarini, J. Etcheverry, E. Gatto, J. Ziliani, G. Da Prat, N. Gonzalez Rojas, V. Parisi, G. Persi (Buenos Aires, Argentina)

  • Level of serum Mortalin in Parkinson’s disease correlating with -Synuclein: Assessment of protein marker for early detection

    S. Dey, A. Singh, T. Bajaj, A.B. Dey (New Delhi, India)

  • Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype

    YJ. Tan, A. Ng, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

  • Levodopa and subthalamic stimulation do not have the same effect on subjective cost for distal and axial efforts in Parkinson’s disease

    C. Atkinson-Clement, E. Cavazzini, C. Baunez, A. Zénon, S. Pinto, F. Fluchère, E. Robin, T. Witjas, JP. Azulay, A. Eusebio (Aix-en-Provence, France)

  • Levodopa Effect on Dual-Tasking in Freezing of Gait in Parkinson’s Disease

    E. Bayram, J. Longhurst, S. Banks, Z. Mari, B. Bluett (Las Vegas, NV, USA)

  • Levodopa effect on non-motor symptoms in late stage Parkinson’s disease

    K. Rosqvist, P. Odin, P. Hagell, S. Iwarsson, M. Nilsson, A. Storch (Lund, Sweden)

  • Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)

    M. Lin, R. Laureno (Washington, DC, USA)

  • Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study

    K. Thiankhaw, S. Tanprawate, A. Soontornpun, A. Nudsasarn, S. Chankrachang (Chiang Mai, Thailand)

  • Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters

    N. Amato, M. Manconi, J.C. Möller, S. Sarasso, P. Stanzione, C. Städler, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

  • Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)

    P. Turcano, M. Mielke, C. Stang, J. Bower, J. Parisi, J. Cutsforth Gregory, E. Ahlskog, R. Savica (Rochester, MN, USA)

  • Levosulpiride Induced Movement Disorder: 7 cases

    D. Radhakrishnan, V. Goyal (New Delhi, India)

  • Lewy body disease with visual hallucination: Optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

    M. Miyata, S. Kakeda, T. Yoneda, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

  • Life Expectancy for Parkinson Patients at Hoehn and Yahr Stage 5

    W. Li, H.L. Ng, S. Acharyya, K.Y. Tay, W.L. Au, L. Tan (Singapore, Singapore)

  • Likelihood ratios of prodromal diagnostic markers for Chinese Parkinson’s disease: A systematic review and meta-analysis

    S.Y. Liu, Z. Zheng, Z.Q. Gu, C.D. Wang, P. Chan (Beijing, China)

  • Linking neuroplastic effects to behavioral changes after balance training in Parkinson’s disease: a study protocol of a randomized controlled trial

    E. Franzén, H. Johansson, M. Freidle, U. Ekman, E. Schalling, A. Lebedev, M. Lövdén, S. Holmin, P. Svenningsson, M. Hagströmer (Huddinge, Sweden)

  • Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease

    C. Sung, M. Danoudis, R. Iansek (Melbourne, Australia)

  • Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson’s disease patients with the LRRK2 mutation?

    C. Carricarte Naranjo, C. Marras, N. Visanji, D. Cornforth, L. Sanchez-Rodriguez, B. Schuele, S. Goldman, M. Estévez Báez, P. Stein, A. Lang, H. Jelinek, A. Machado García (Havana, Cuba)

  • Local field potential changes during sleep in the PSA of patients with essential tremor

    L. Mueller, A. Auchter, M. Reich, F. Steigerwald, J. Volkmann (Wuerzburg, Germany)

  • Long term clinical outcome after deep brain stimulation of the thalamic VIM in Holmes Tremor: A case series

    J. Becktepe, S. Paschen, F. Goevert, A. Helmers, G. Deuschl (Kiel, Germany)

  • Long Term Outcome of the Subthalamic Nucleus DBS for Advanced Parkinson’s Disease: An Eight Years Follow-Up Study in China

    Q. Guo, J. Liu, C. Yang, W. Xian, L. Jiang, S. Xu, W. Chen, Y. Hu, L. Chen (Guangzhou, China)

  • Long Term Response to L-dopa in Parkinson Disease

    H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

  • Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies

    R. Cilia, E. Cereda, A. Akpalu, S. Sarfo, M. Cham, G. Pezzoli (Milan, Italy)

  • Long-term and dopamine dependent dynamics of subthalamic nucleus local field potentials in Parkinson’s disease

    N. Drummond, K. Udupa, U. Saha, T. Hoque, J. Saravanamuttu, A. Fasano, A. Lozano, M. Hodaie, S. Kalia, R. Chen (Toronto, ON, Canada)

  • Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD

    T. Xie, L. Bloom, M. Padmanaban, B. Bertacchi, W. Kang, A. Dachman, E. MacCracken, C. Zadikoff, K. Markopoulou, P. Warnke, U. Kang (Chicago, IL, USA)

  • Long-term effect of subthalamic nucleus deep brain stimulation on freezing of gait in patients with advanced Parkinson’s disease

    R. Kim, C.W. Shin, H. Park, A. Kim, H.J. Kim, S.H. Paek, B. Jeon (Seoul, Republic of Korea)

  • Long-term effects of music as an auditory cue on motor and non-motor symptoms of Parkinson’s disease: A case report

    F. Lindop, R. Skelly (Derby, United Kingdom)

  • Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions

    F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

  • Long-term habituation of deep brain stimulation for essential tremor: An observer-blinded study

    S. Paschen, J. Forstenpointner, J. Becktepe, H. Hellriegel, K. Witt, AK. Helmers, G. Deuschl (Kiel, Germany)

  • Long-term Outcomes with Rescue Target Deep Brain Stimulation in Patients with Dystonia

    A. Hatcher, A W. Shukla, P. Zeilman, E. Ofori, D. Vaillancourt, K. Foote, M. Okun (Gainesville, FL, USA)

  • Longitudinal alpha-synuclein in cerebrospinal fluid in early Parkinson’s disease, prodromal PD and healthy controls

    B. Mollenhauer, C. Caspell-Garcia, C. Coffey, P. Taylor, A. Singleton, L. Shaw, J. Trojanowski, M. Frasier, T. Simuni, A. Siderowf, K. Marek, D. Galasko (Kassel, Germany)

  • Longitudinal changes in Neuromelanin MRI Signal in Parkinson’s Disease

    R. Gaurav, N. Pyatigorskaya, C. Ewenczyk, R. Valabregue, K. Evans, I. Arnulf, M. Vidailhet, S. Lehéricy (Paris, France)

  • Longitudinal decline in white matter integrity in Parkinson’s disease: An analysis of Parkinson Progression Markers Initiative diffusion tensor imaging data

    K. Taylor, F. Sambataro, A. Bertolino, J. Dukart (Basel, Switzerland)

  • Longitudinal development of nigral iron load in Parkinson’s Disease

    S. Franthal, L. Pirpamer, C. Rodler, N. Homayoon, M. Koegl, P. Katschnig-Winter, K. Wenzel, C. Langkammer, S. Ropele, R. Schmidt, P. Schwingenschuh (Graz, Austria)

  • Longitudinal follow-up of dual-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor

    B. Patel, R. Barmore, A. Elkouzi, P. Zeilman, X. Bai, L. Almeida, K. Foote, M. Okun (Gainesville, FL, USA)

  • Longitudinal MRI to predict cognitive impairment in Parkinson’s disease

    T. Melzer, D. Myall, L. Livingston, M. Almuqbel, M. MacAskill, T. Pitcher, K. Horne, S. Grenfell, M. Pascoe, D. Miller, R. Keenan, J. Dalrymple-Alford, T. Anderson (Christchurch, New Zealand)

  • Longitudinal observational study on late onset Parkinson’s disease over a decade

    S. Raha, L. Ebenezer (Bridgend, United Kingdom)

  • Loss of paraplegin drives spasticity rather than ataxia in SPG7: A European cohort analysis of 238 patients

    G. Coarelli, R. Schule, B. vande Warrenburg, P. de Jonghe, C. Ewenczyk, A. Martinuzzi, M. Synofzik, E. Hamer, J. Baets, M. Anheim, L. Schöls, T. Deconinck, B. Fontaine, T. Klockgether, MG. D'Angelo, ML. Monin, P. Charles, MT. Bassi, T. Klopstock, E. Ollagnon-Roman, C. Kamm, M. Papin, CS. Davoine, G. Banneau, S. Tezenasdu Montcel, D. Seilhean, A. Brice, C. Duyckaerts, G. Stevanin, A. Durr (Paris, France)

  • Loss of VPS29 disrupts retromer function and synaptic transmission, leading to neurodegeneration in Drosophila

    H. Ye, D. Li-Kroeger, Y. Li, H. Bellen, J. Shulman (Houston, TX, USA)

  • Lottery choice task as a detect tool for PD patients with pathological gambling

    W. Liu, R. Wu, J. Goh (Hualien, Taiwan)

  • Low body weight is associated with poor functional status in Parkinson’s disease (PD)

    HF. Chan, N. Cheung, D. Chau, CW. Woo, B. Chee, A. Leung, S. Or, WC. Fong (Hong Kong)

  • Low-Fat Versus Ketogenic Diet In Parkinson’s Disease: A Pilot Randomized Controlled Trial

    M. Phillips, D. Murtagh, L. Gilbertson, F. Asztely, C. Lynch (Hamilton, New Zealand)

  • LRRK2 and GBA genetic mutations are not uncommon in an unselected Ashkenazi elderly cohort with PD

    S. Isaacson, J. Isaacson (Boca Raton, FL, USA)

  • LRRK2 p.Leu119Pro and p.Leu488Pro in a family with neuropathologycally confirmed Parkinson´s disease without Lewy bodies

    L. Vela-DeSojo, J. Hoenicka, P. Pire-Garcia, C. Guerrero, M. Osuna-Lopez, S. Ocaña-Lopez (Alcorcón, (Madrid), Spain)

  • Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation

    S. Jamwal, P. Kumar (Baddi, India)

  • Lysosphingolipids accumulation in macrophage model of Gaucher disease

    M. Nikolaev, A. Kopytova, K. Senkevich, A. Emelyanov, G. Baydakova, E. Zakharova, G. Salogub, S. Pchelina (Gatchina, Russian Federation)

Jump to:  View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley